Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 117

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 117
---

  
    Cash,
    end of year 
    $2,832,931  
    $4,602,566 

    Supplemental
    disclosure of cash flow information 

    Cash
    paid for interest 
    $-  
    $- 
  
    Cash
    paid for income taxes 
    $-  
    $- 
  
    Supplemental
    schedule of non-cash financing activities: 

    Deferred
    offering costs charged to additional paid-in capital 
    $32,500  
    $426,345 

See
notes to consolidated financial statements

F-7

MIRA
PHARMACEUTICALS, INC.

SUPPLEMENTAL
CASH FLOW INFORMATION

Non-cash
financing and investing activities:

The
Company recorded deferred offering costs of $32,500 during the year ended December 31, 2024 in association with the At the Market Agreement
and charged these costs to additional paid in capital.

The
Company recorded the fair value of a total of 1,000,000 shares of common stock issued to Bay Shore Trust during the year ended December
31, 2023 which totaled approximately $3.5 million to deferred finance costs. The Company had amortized approximately $0.7 million of
deferred offering costs as non-cash amortization of debt issuances costs in accordance with Generally Accepted Accounting Principles
(“GAAP”). As of December 31, 2023, this agreement was paid in full. This resulted in a write-off of unamortized deferred
financing costs, in the amount of $2.8 million which was recorded as interest expense.

The
Company recorded the fair value of a total of 157,170 shares of common stock issued to Bay Shore Trust during the year ended December
31, 2023 totaling approximately $1.1 million to record Bay Shore Trust conversions of a line of credit and interest to shares of common
stock.

The
Company recorded the fair value of a total of 35,715 shares of common stock issued to the MZ Group during the year ended December 31,
2023 totaling $0.25 million in lieu of fees for investor relation services.

On
November 15, 2023, the Company entered a warrant agreement and recorded the fair value of a total of 700,000 shares of common stock issued
to MIRALOGX, LLC which totaled $1,832,600 to expense